Heart Failure Medicines Pocket Card 2026

An updated pocket card on heart failure medicines for pharmacy and medical students: HF types, the four pillars of HFrEF treatment with doses, the new HFpEF treatment, diuretics and add-on drugs, safe titration and drugs to avoid, based on the 2026 ESC heart failure guideline and the 2026 ACC HFpEF pathway.

Heart Failure Medicines Pocket Card 2026
Chronic heart failure in adults · based on 2026 ESC guideline and 2026 ACC HFpEF pathway
FMT foundational medical therapy (start all, at low dose, within weeks)   Add additional therapy   Avoid harmful in heart failure  |  EF = ejection fraction · OD = once daily · BD = twice daily
Types & diagnosis
  • HFrEF (ESC 2026): EF under 50% with symptoms (the old "mildly reduced" group is now included)
  • HFpEF: EF 50% or more with symptoms and evidence of raised filling pressure
  • US (ACC/AHA 2022): still uses HFrEF 40% or less, HFmrEF 41 to 49%, HFpEF 50% or more
  • Tests: NT-proBNP (over 125 pg/mL outpatient), echocardiogram, ECG, kidney function, potassium, iron studies
  • Symptoms: breathlessness, orthopnoea, ankle swelling, tiredness; NYHA class I to IV
HFrEF: the four pillars
  • FMT ARNI / ACEi / ARB: sacubitril/valsartan 24/26 mg BD up to 97/103 mg BD (36-h gap after ACEi); or ramipril 1.25 up to 5 mg BD, enalapril 2.5 up to 10 to 20 mg BD; candesartan 4 up to 32 mg OD, valsartan 40 up to 160 mg BD
  • FMT Beta-blocker: bisoprolol 1.25 up to 10 mg OD; carvedilol 3.125 up to 25 mg BD; metoprolol succinate 12.5 up to 200 mg OD; nebivolol 1.25 up to 10 mg OD
  • FMT MRA: spironolactone 12.5 to 25 up to 50 mg OD; eplerenone 25 up to 50 mg OD (potassium under 5.0, eGFR over 30)
  • FMT SGLT2 inhibitor: dapagliflozin 10 mg OD or empagliflozin 10 mg OD; no titration; with or without diabetes (eGFR 20 to 25 or more)
  • How: start all four early at low doses; double doses every 2 to 4 weeks as tolerated
HFpEF treatment
  • FMT SGLT2 inhibitor: dapagliflozin or empagliflozin 10 mg OD
  • FMT MRA: finerenone favoured (ACC 2026; approved for EF 40% or more): eGFR 60 or more start 20 mg OD, target 40 mg; eGFR 25 to 59 start 10 mg OD, target 20 mg; recheck potassium and eGFR at 4 weeks. Or spironolactone
  • Obesity (BMI 30 or more): semaglutide or tirzepatide: better symptoms, exercise capacity and weight
  • Congestion: loop diuretic at the lowest dose that keeps the patient dry
  • Treat causes: control BP, atrial fibrillation, diabetes, sleep apnoea, kidney disease
Diuretics & additional drugs
  • Loop diuretics: furosemide 20 to 40 mg OD (up to 240 mg); torasemide 5 to 20 mg; bumetanide 0.5 to 1 mg; for symptoms only, no survival benefit
  • Add Ivabradine: 5 mg BD up to 7.5 mg BD; sinus rhythm with heart rate 70 or more despite max beta-blocker
  • Add Vericiguat: 2.5 mg OD up to 10 mg OD after a recent worsening
  • Add Digoxin: 62.5 to 250 micrograms OD for symptoms or AF; keep level 0.5 to 0.9 ng/mL
  • Add Hydralazine + ISDN: if ACEi/ARB/ARNI not tolerated, or in Black patients
  • Add IV iron: ferric carboxymaltose or derisomaltose if ferritin under 100, or 100 to 299 with TSAT under 20%
Monitoring & safe titration
  • Bloods: potassium and creatinine 1 to 2 weeks after each start or dose rise
  • Creatinine: rise up to 30 to 50% is acceptable; do not stop drugs automatically
  • Potassium: 5.5 or less: continue; 5.5 to 6.0: halve MRA/RAS dose; over 6.0: stop and recheck
  • Low BP: if no symptoms, keep going; first reduce diuretics or other BP drugs
  • Daily weight: call the doctor if weight rises more than 2 kg in 3 days
  • Hospital: start SGLT2 inhibitor in hospital once stable; do not stop beta-blocker unless shock
Avoid or use with care
  • Avoid NSAIDs: fluid retention, kidney injury, worsening HF
  • Avoid Diltiazem / verapamil: negative inotropes, harmful in HFrEF
  • Avoid Pioglitazone: fluid retention
  • Avoid Saxagliptin, alogliptin: increase HF admissions
  • Avoid Class I antiarrhythmics, dronedarone: increase deaths in HFrEF; use amiodarone if needed
  • Avoid ACEi + ARNI together: angioedema; also avoid ACEi + ARB + MRA triple
  • Others: high-salt effervescent tablets, steroids, some cancer drugs (anthracyclines, trastuzumab)
Typical adult doses (start low, increase slowly). Always follow local guidelines and the cardiologist. Sources: 2026 ESC Heart Failure Guidelines; 2026 ACC Expert Consensus Decision Pathway for HFpEF; 2022 AHA/ACC/HFSA Heart Failure Guideline.

Details behind the card

1. What changed in 2026?

  • Only two types (ESC 2026): HFrEF is now EF under 50% and HFpEF is EF 50% or more. The "mildly reduced" (HFmrEF) category was removed.
  • New names: "guideline-directed medical therapy" is split into foundational medical therapy (beta-blocker, ACEi/ARNI/ARB, MRA, SGLT2 inhibitor) and additional medical therapy (ivabradine, vericiguat, digoxin). Acute heart failure is now called decompensated heart failure.
  • MRAs and SGLT2 inhibitors get the strongest (Class I) recommendation in symptomatic heart failure at any EF.
  • HFpEF with obesity: semaglutide or tirzepatide recommended for the first time in the ESC guideline (Class IIa).
  • ACC 2026 HFpEF pathway: SGLT2 inhibitor plus finerenone is the backbone; finerenone is preferred over spironolactone.
  • In hospital: start SGLT2 inhibitors after stabilisation and guide diuretics by urine sodium.

2. Why each pillar works

Drug groupHow it helpsMain side effects
ARNI (sacubitril/valsartan)Blocks angiotensin and boosts natriuretic peptides that open vessels and remove saltLow BP, high potassium, angioedema
ACEi / ARBBlock the renin-angiotensin system, reduce strain and remodellingCough (ACEi), high potassium, kidney function changes
Beta-blockersSlow heart rate, protect against adrenaline, improve EF over monthsTiredness, slow pulse, temporary worsening at start
MRABlock aldosterone: less fibrosis and salt retentionHigh potassium; gynaecomastia with spironolactone
SGLT2 inhibitorsMild diuresis, better heart energy use, protect kidneysGenital infection, dehydration, rare euglycaemic DKA
Loop diureticsRemove excess fluidLow potassium, dehydration, kidney injury, gout

3. Practical tips for pharmacists

  • Changing from ACEi to ARNI: stop the ACEi and wait 36 hours before the first ARNI dose.
  • Beta-blockers: only bisoprolol, carvedilol, metoprolol succinate (and nebivolol in ESC) have proven benefit; metoprolol tartrate and atenolol do not.
  • Do not combine spironolactone with potassium supplements or salt substitutes containing potassium.
  • Patients should weigh themselves every morning after passing urine, before breakfast.
  • A flexible diuretic plan helps: an extra dose if weight rises, a lower dose if dizzy or dehydrated.
  • Fluid restriction (1.5 to 2 L/day) only for severe symptoms or low sodium; keep salt moderate.
  • Annual flu and pneumococcal vaccines are recommended.

4. Decompensated (acute) heart failure in brief

  • Wet and warm (most common): IV loop diuretic, usually 1 to 2.5 times the home oral dose; check urine output and urine sodium.
  • Cold and wet (low output): specialist care, may need inotropes.
  • Oxygen only if saturation is under 90%; nitrates if BP is high.
  • Continue foundational drugs where possible and start an SGLT2 inhibitor before discharge.

5. Special situations

  • Kidney disease: SGLT2 inhibitors can be started at eGFR 20 to 25 or more; MRAs need eGFR over 30 and close potassium checks.
  • Atrial fibrillation: beta-blocker for rate control (digoxin as add-on); anticoagulation by stroke risk.
  • Pregnancy: ACEi, ARB, ARNI, MRA and SGLT2 inhibitors are contraindicated; use specialist care (hydralazine, nitrates, beta-blocker).
  • Diabetes: prefer SGLT2 inhibitors and GLP-1 RAs; avoid pioglitazone and saxagliptin.

Remember for exams

  • HFrEF four pillars: ARNI/ACEi/ARB, beta-blocker, MRA, SGLT2 inhibitor.
  • ESC 2026: HFrEF is EF under 50%; HFmrEF removed.
  • Wait 36 hours between ACEi and ARNI.
  • Loop diuretics relieve symptoms but do not improve survival.
  • Avoid NSAIDs, diltiazem/verapamil and pioglitazone in HFrEF.
  • HFpEF: SGLT2 inhibitor + MRA (finerenone), and semaglutide/tirzepatide if obese.

Sources

  • 2026 ESC Guidelines for the diagnosis and treatment of heart failure. European Heart Journal, 2026.
  • 2026 ACC Expert Consensus Decision Pathway for the management of HFpEF. JACC, July 2026.
  • 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
  • Product information (SmPC) for individual drugs.

Important: this card is for education and revision. Treatment decisions must follow local guidelines and the treating doctor. More pocket cards: Clinical Pocket Cards

No comments:

Post a Comment